Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, 19104, USA.
Curr Atheroscler Rep. 2010 Jul;12(4):230-5. doi: 10.1007/s11883-010-0116-5.
With the advent of new therapeutic options for acute ischemic stroke, expeditious evaluation of patients with suspected stroke has become imperative. Goals of the initial evaluation are to determine the time of symptom onset, severity of the neurologic deficit, and to exclude intracranial hemorrhage and other mimics of acute ischemic stroke. CT and MRI perfusion studies may demonstrate the presence of an ischemic penumbra and aid in identification of patients who may benefit from thrombolysis. Intravenous recombinant tissue plasminogen activator (IV rtPA) remains the gold standard for acute ischemic stroke treatment, and the therapeutic time window recently has been extended to 4.5 h in certain patients. Catheter-based intra-arterial thrombolysis is being used increasingly as "rescue therapy" after IV rtPA and as primary therapy in select patients who are ineligible for intravenous therapy. Trials investigating the efficacy and safety of intra-arterial therapy are ongoing.
随着急性缺血性脑卒中治疗新选择的出现,对疑似脑卒中患者进行快速评估已变得至关重要。初步评估的目的是确定症状发作的时间、神经功能缺损的严重程度,并排除颅内出血和其他急性缺血性脑卒中的类似疾病。CT 和 MRI 灌注研究可以显示缺血半暗带的存在,并有助于识别可能从溶栓治疗中获益的患者。静脉注射重组组织型纤溶酶原激活剂(IV rtPA)仍然是急性缺血性脑卒中治疗的金标准,治疗时间窗最近已在某些患者中延长至 4.5 小时。在接受 IV rtPA 治疗后,基于导管的动脉内溶栓治疗越来越多地被用作“挽救性治疗”,并且在某些不符合静脉治疗条件的患者中作为主要治疗方法。正在进行临床试验以评估动脉内治疗的疗效和安全性。